Analysts Expect AVEO Pharmaceuticals (AVEO) Stock to Gain 95%

Tuesday, September 10, 2019 10:02 AM | InvestorsObserver Analysts

AVEO Pharmaceuticals, Inc. (AVEO) stock is lower by -69.59% over the last 12 months, and the average rating from Wall Street analysts is a Moderate Buy. Stock Score Report, InvestorsObserver’s proprietary scoring system, gives AVEO stock a score of 53 out of a possible 100.

That score is chiefly influenced by a fundamental score of 61. In addition to the average rating from Wall Street analysts, AVEO stock has a mean target price of $1.75. This means analysts expect the stock to climb 94.45% over the next 12 months. AVEO’s score also includes a short-term technical score of 58. The long-term technical score for AVEO is 41.

Click Here to get the full Stock Score Report on AVEO Pharmaceuticals, Inc. (AVEO).

What’s Happening with AVEO Stock Today

AVEO Pharmaceuticals, Inc. (AVEO) stock is higher by 27.03% while the S&P 500 is lower by -0.65% as of 9:48 AM on Tuesday, Sep 10. AVEO has risen $0.19 from the previous closing price of $0.71 on volume of 7,070,896 shares. Over the past year the S&P 500 is up 2.85% while AVEO is lower by -69.59%. AVEO lost -$0.02 per share in the over the last 12 months.

Related Companies

InvestorsObserver Cyber Week Sale

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium

InvestorsObserver Premium

$ 29 $ 14.50 /month

Related Articles

Cronos Group (CRON) Stock: How Does it Score?

Lipocine (LPCN) Stock: What’s Next?

Should You Buy Dare Bioscience (DARE) Stock Monday?

Should You Buy Clovis Oncology (CLVS) Stock Monday?

Novus Therapeutics (NVUS) Stock Falls -18.6%: How Does it Score?

Analysts Expect Protalix Biotherapeutics (PLX) Stock to Rises 540%; Rated Strong Buy

Related Companies